Literature DB >> 6580648

Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

P M Capone, L D Papsidero, G A Croghan, T M Chu.   

Abstract

Two distinct monoclonal antibodies (mAbs) were effective in the therapy of breast carcinomas of human origin established and growing in nude mice. Passive administration of either of the antibodies produced very rapid (less than 1 week) and significant reduction of in vivo tumor volume. Each of the mAbs showed in vivo targeting of the tumors. Histological analysis of mAb-treated tumors revealed extensive cellular necrosis. Each of the antibodies in vitro was effective in complement-mediated cytolysis at a concentration less than 1 ng/ml. The tumoricidal responses show that this is a useful model for passive human immunotherapy using mAbs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580648      PMCID: PMC390048          DOI: 10.1073/pnas.80.23.7328

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

2.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

Authors:  D M Herlyn; Z Steplewski; M F Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

3.  Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies.

Authors:  E C Ward; J D Iglehart; K J Weinhold; D P Bolognesi
Journal:  J Natl Cancer Inst       Date:  1982-08       Impact factor: 13.506

4.  Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

Authors:  I D Bernstein; M R Tam; R C Nowinski
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

5.  Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma.

Authors:  L D Papsidero; G A Croghan; M J O'Connell; L A Valenzuela; T Nemoto; T M Chu
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

6.  Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.

Authors:  M E Kirch; U Hammerling
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

7.  Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22.

Authors:  G A Croghan; L D Papsidero; L A Valenzuela; T Nemoto; R Penetrante; T M Chu
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

Review 8.  Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

Authors:  J Ritz; S F Schlossman
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

9.  Inhibition of tumor growth by monoclonal anti-I-J antibodies.

Authors:  J A Drebin; C Waltenbaugh; S Schatten; B Benacerraf; M I Greene
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

10.  A sensitive assay for the detection cytotoxic antibodies to mammalian cell surface antigens.

Authors:  J M Brown; W P Thorpe; S A Rosenberg
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

View more
  11 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  A monoclonal antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice.

Authors:  Y Fukuda; K Imai; K Miura; M Matsui; T Nakanishi; H Nakazato; J Masukawa; T Higashide; Y Hinoda; T Noguchi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Authors:  K E Odening; W Li; R Rutz; S Laufs; S Fruehauf; Z Fishelson; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

5.  Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.

Authors:  I Bergman; E Arbit; M Rosenblum; S M Larson; G Heller; N K Cheung
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

6.  Persistent complement activation on tumor cells in breast cancer.

Authors:  F Niculescu; H G Rus; M Retegan; R Vlaicu
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

7.  Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody.

Authors:  P M Capone; N Kadohama; T M Chu
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody.

Authors:  J R Corvalan; W Smith; V A Gore; D R Brandon; P J Ryde
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.

Authors:  N K Cheung; E I Walter; W H Smith-Mensah; W D Ratnoff; M L Tykocinski; M E Medof
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

Review 10.  Podoendin. A new cell surface protein of the podocyte and endothelium.

Authors:  T W Huang; J C Langlois
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.